Results 41 to 50 of about 16,658,609 (280)

The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer

, 2023
Breast cancer represents one of the most common tumor histologies. To date, based on the specific histotype, different therapeutic strategies, including immunotherapies, capable of prolonging survival are used. More recently, the astonishing results that
Caterina Gianni, Michela Palleschi, Ugo De Giorgi, Giuseppe Schepisi, Chiara Casadei, Cristian Lolli, Sara Bleve, Laura Ridolfi, Giovanni Martinelli   +8 more
core   +1 more source

Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia

Journal for ImmunoTherapy of Cancer, 2023
The treatment of B cell malignancies has dramatically changed with the introduction of immunotherapy, especially chimeric antigen receptor T (CAR-T) cell therapy. However, only limited efficacy is observed in acute myeloid leukaemia (AML).
Ting Yang, Jingjing Wen, Yanxin Chen, Jiajie Yang, Chunye Dai, Shenjie Yu, Wenting Zhong, Lilin Liu, Chengguanng He, Wenmin Zhang, Lingfeng Liu, Jianda Hu   +11 more
doaj   +1 more source

Evaluation of Toxicity Associated with CAR-T Cell Therapy and Nursing Interventions [PDF]

Objective: Chimeric antigen receptor (CAR)-T cell therapy is a new immunotherapy approach that has started to been used in recent years and is developing rapidly.
Gülbeyaz CAN, Seçkin ERDAL, Sevinç SELÇUK, Ayşem KÜNİ   +3 more
core   +1 more source

Nephrotoxicity in CAR-T Cell Therapy

Transplantation and Cellular Therapy
Chimeric antigen receptor (CAR)-T cell therapy is a novel therapy for the treatment of different hematologic malignancies. Besides its efficiency, CAR-T cell therapy is associated with significant toxicity, primarily manifested as cytokine release syndrome (CRS) and neurotoxicity.
Karol Sadowski, Weronika Ploch, Alicja Downar, Wiktoria Giza, Dorota Szcześ, Wioletta Olejarz, Wiesław W. Jędrzejczak, Jolanta Małyszko, Grzegorz Basak   +8 more
openaire   +2 more sources

The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies

ImmunoMedicine, 2022
Chimeric antigen receptors (CAR) T‐cell therapy is one of the most effective treatments in curing hematologic malignancies. Besides the four CD19 CAR T‐cells therapy recently approved by the US Food and Drug Administration (FDA), CD20 CAR T‐cell therapy ...
Elaine Tan Su Yin, Yong Xian Hu, He Huang   +2 more
doaj   +1 more source

HLA‐Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy [PDF]

, 2008
We assessed the influence of human leukocyte antigen (HLA) alleles HLA-Bw4 and HLA-Bw6 on CD4 T cell recovery after starting successful combination antiretroviral therapy in 265 individuals. The median gains in the CD4 T cell count after 4 years were 258
Battegay, Manuel, Günthard, Huldrych F, Gaudieri, S., Swiss, HIV Cohort Study, John, Mina, Nolan, David, James, Ian, Furrer, H, Schmid, P, Battegay, M., McKinnon, E, Rauch, A., Swiss HIV Cohort Study, ., McKinnon, E., Telenti, A, Günthard, Huldrych F., Schmid, Patrick, Rauch, A, John, M., James, I, Furrer, Hansjakob, Hirschel, Bernard, Telenti, Amalio, Schmid, P., Furrer, H., Rauch, Andri, John, M, Günthard, H.F., Mallal, Simon, Telenti, A., McKinnon, Elizabeth, Nolan, D., Günthard, H F, Hirschel, B, Günthard, H. F., Battegay, M, Hirschel, B., Nolan, D, Mallal, S, James, I., Gaudieri, Silvana, Mallal, S., Gaudieri, S   +42 more
core   +2 more sources

CAR T-Cell Therapy: Progress and Prospects

, 2017
Lentivirus-mediated transduction of autologous T cells with a chimeric antigen receptor (CAR) to confer a desired epitope specificity as a targeted immunotherapy for cancer has been among the first human gene therapy techniques to demonstrate widespread ...
Flotte, Terence R., Wilkins, Olivia, Keeler, Allison M   +2 more
core   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Bystander CAR−CD8+ T cells in a CAR-T cell product can expand and enhance the antitumor effects of a bispecific antibody

Journal for ImmunoTherapy of Cancer
Although bispecific antibody (BsAb) treatment is a valuable therapeutic option for post chimeric antigen receptor (CAR)-T cell therapy against relapsed/refractory large B-cell lymphoma, it remains to be clarified why it is still effective after intensive
Toshiki Ochi, Tatsuya Konishi, Jun Yamanouchi, Takatsugu Honda, Katsuto Takenaka, Junichi Kato, Masaki Maruta, Shogo Nabe, Yuya Masuda, Meika Matsumoto, Natsumi Kawasaki, Yukihiro Miyazaki, Yasukazu Doi, Yasunori Takasuka   +13 more
doaj   +1 more source

Characterization of the effect of T cell killing ability and resistance to environmental ROS on the efficiency of CAR-T cell Immunotherapy

, 2023
reservedChimeric Antigens Receptor (CAR) T cells adoptive transfer represents a revolutionary strategy in cancer treatment. Indeed, anti-CD19 CAR T cells therapy has dramatically changed the fate of patients with relapsed/refractory (r/r)diffuse large ...
DARBAN, HANIEH
core